Current Opinion in Hematology volume 17, issue 6, P522-530 2010 DOI: 10.1097/moh.0b013e32833e5b41 View full text
Paolo Corradini, Lucia Farina

Abstract: Although the nonrelapse mortality has been reduced and survival curves show a plateau, the analysis of the long-term outcome reveals that a significant proportion of patients still experiences disease relapse and delayed morbidity and mortality. At the best of our knowledge, the process of decision-making should be based on lymphoma subtype, chemosensitivity, disease status and patient comorbidities at the time of allografting. To answer some of the still open questions, physicians should try to improve the en…

expand abstract